神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/0100485310

このアイテムのアクセス数:113件（2025-08-02 21:38 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
0100485310 (fulltext) pdf 3.51 MB 77

メタデータ

ファイル出力

メタデータID
0100485310
アクセス権
open access
出版タイプ
Version of Record
タイトル
Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project
著者
Shimoyama, Rai ; Imamura, Yoshinori ; Uryu, Kiyoaki ; Mase, Takahiro ; Fujimura, Yoshiaki ; Hayashi, Maki ; Ohtaki, Megu ; Ohtani, Keiko ; Shinozaki, Nobuaki ; Minami, Hironobu
著者名
Shimoyama, Rai
著者ID
A2078
研究者ID
1000080796160
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=faae382bacd342f9520e17560c007669
著者名
Imamura, Yoshinori
今村, 善宣
イマムラ, ヨシノリ
所属機関名
医学研究科
著者名
Uryu, Kiyoaki
著者名
Mase, Takahiro
著者名
Fujimura, Yoshiaki
著者名
Hayashi, Maki
著者名
Ohtaki, Megu
著者名
Ohtani, Keiko
著者名
Shinozaki, Nobuaki
著者ID
A1398
研究者ID
1000060450574
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=29f74a5e8b26a0a9520e17560c007669
著者名
Minami, Hironobu
南, 博信
ミナミ, ヒロノブ
所属機関名
医学研究科
言語
English (英語)
収録物名
Molecular and Clinical Oncology
巻(号)
19(6)
ページ
98
出版者
Spandidos Publications
刊行日
2023-12
公開日
2023-11-30
抄録
The present study aimed to investigate temporal trends in treatment patterns and prognostic factors for overall survival (OS) among patients with metastatic pancreatic cancer. From the Tokushukai REAl‑world Data project, 1,093 patients with metastatic pancreatic cancer treated with gemcitabine, tegafur/gimeracil/oteracil (S‑1), gemcitabine plus S‑1, gemcitabine plus nab‑paclitaxel, or fluorouracil, folic acid, oxaliplatin and irinotecan (FOLFIRINOX) between April 2010 and March 2020 were identified. Stratified/conventional Cox regression analyses were conducted to examine associations between patient‑ and tumor‑related factors, study period, hospital volume, hospital type and first‑line chemotherapy regimens. Overall, 846 patients were selected (503 male patients; median age, 70 years) after excluding ineligible patients. Over a median follow‑up of 5.4 months, the median OS was 6.8 months (95% confidence interval, 6.3‑7.4). The median OS for gemcitabine, S‑1, gemcitabine plus S‑1, gemcitabine plus nab‑paclitaxel and FOLFIRINOX regimens was 5.9, 5.3, 7.7, 9.0 and 9.5 months, respectively. The median OS for 2010‑2013, 2014‑2017 and 2017‑2020 was 6.2, 7.1 and 7.8 months, respectively. Performance status, body mass index and first‑line chemotherapy regimens were identified to be significant prognostic factors. In summary, the real‑world data indicated that standard care, including chemotherapy, for metastatic pancreatic cancer was widely used in hospitals throughout Japan and verified the survival benefits of gemcitabine plus nab‑paclitaxel and FOLFIRINOX observed in prior clinical trials. This trial has been registered in the University Hospital Medical Information Network Clinical Trials Registry as UMIN000050590 on April 1, 2023.
キーワード
chemotherapy
metastatic pancreatic cancer
RWD
FOLFIRINOX
gemcitabine plus nab‑paclitaxel
カテゴリ
医学研究科
学術雑誌論文
権利
© Shimoyama et al.
CC license
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.
関連情報
DOI
https://doi.org/10.3892/mco.2023.2694